BioCentury
ARTICLE | Finance

New Navigator

VCs bet Navitor's MTOR selectivity approach will best rapamycin products

June 23, 2014 7:00 AM UTC

Navitor Pharmaceuticals Inc. is betting selective inhibitors of mammalian target of rapamycin complex 1 (mTORC1) will lead to reduced toxicity compared to drugs targeting both mTORC1 and mTORC2, and expects it will be able to take its hypothesis into the clinic with a new $23.5 million series A round.

Polaris Partners; Atlas Venture; Johnson & Johnson Development Corp. (JJDC); SR One; and The Longevity Fund participated in last week's tranched round. JJDC is the venture arm of Johnson & Johnson (NYSE:JNJ)...